LONDON, March 07, 2017 — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer Justin Gover, […]

by

The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast […]

by

LONDON, March 07, 2017 — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer Justin Gover, […]

by

Whenever Jessie Opoien | The Capital Times posts new content, you’ll get an email delivered to your inbox with a link. Email notifications are only sent once a day, and only if there are new matching items. … read more at: http://host.madison.com/ct/news/local/govt-and-politics/election-matters/wisconsin-democrats-introduce-bills-aimed-at-legalizing-medical-marijuana/article_e96d56c7-5fb0-50b5-917e-97421493f37e.html

by

Hollywood, March 14, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc. the nomination of Kim Foster-Cunningham […]

by

Hollywood, March 14, 2017 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc. the nomination of Kim Foster-Cunningham […]

by

DEVON, Pa., March 13, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel […]

by

DEVON, Pa., March 13, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel […]

by

The report indicates that the increasing interest amongst academic researchers regarding the therapeutic uses of cannabis is one of the most significant factors contributing to the growth of the market. This is due to the effectiveness of cannabis in providing relief to patients suffering from HIV/AIDS, glaucoma, cancer, and multiple sclerosis. The data shows that […]

by

DEVON, Pa., March 13, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel […]

by

Medical Marijuana Inc (OTCMKTS:MJNA) continues to trade a bit soft. There are really two key points of comparison here that make this important. First, the stock has been relatively weak in light of how many press releases and catalysts seem to constantly be pressed into the market from the company. Second, we see plenty of […]

by

NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum. The study is being […]

by

Wrapmail Inc (OTCMKTS:WRAP) is a micro-cap stock that’s clearly begun to spur some interest among players in the marketplace as shares bounce up off recent lows. WRAP stock has been powering higher of late, pushed in part by its recent announcement that they have acquired 100% of HealthMax Group (HealthMaxgroup.com), “thereby entering the multi-billion dollar cannabis […]

by